Daratumumab is always administered by a healthcare professional in a clinical setting, such as a hospital or infusion center. It is given as an intravenous (IV) infusion, which usually takes several hours to complete.

Here are some guidelines for using Daratumumab:

• Administered by Healthcare Professionals: Daratumumab should be given by an experienced healthcare provider. It is infused into your vein through an IV, and the procedure typically takes a few hours.
• Pre-Medications: To reduce the risk of side effects like fever or chills, you may be given other medications (such as antihistamines, corticosteroids, or fever reducers) before the Daratumumab infusion.
• Monitoring: During the infusion, you will be monitored for any side effects. If you experience any symptoms like difficulty breathing, swelling, or a rash, inform the healthcare team immediately.

Daratumumab works by targeting a specific protein called CD38 found on the surface of cancerous multiple myeloma cells. When Daratumumab binds to CD38, it triggers the body’s immune system to attack and kill these myeloma cells. In addition to directly killing the cancer cells, Daratumumab also has effects on the immune system, helping to boost its ability to recognize and destroy the cancer cells more effectively.

It is particularly effective in targeting multiple myeloma cells that are resistant to other treatments.

Like all medications, Daratumumab can cause side effects. Not everyone will experience side effects, but it’s important to be aware of them. Some common side effects include:

• Infusion Reactions: The most common side effects are related to the infusion, such as fever, chills, fatigue, nausea, or breathing difficulties. These often happen during or after the first few infusions and may improve with subsequent treatments.
• Infections: Since Daratumumab affects the immune system, it can increase the risk of infections, including respiratory infections or urinary tract infections (UTIs).
• Low Blood Cell Counts: Daratumumab can cause low levels of red blood cells, white blood cells, and platelets, which may lead to symptoms like fatigue, increased risk of bleeding, or increased risk of infection.
• Fatigue: Many patients report feeling tired or weak after receiving Daratumumab.

Serious Side Effects:

• Severe Infusion Reactions: In rare cases, some people may experience severe allergic reactions to the infusion, such as difficulty breathing, swelling, or chest pain. If any of these symptoms occur, immediate medical attention is required.
• Pneumonia: Daratumumab can increase the risk of lung infections like pneumonia, which can be serious if not treated promptly.

Before starting Daratumumab treatment, consider the following precautions:

• Allergic Reactions: Daratumumab can cause allergic reactions, especially during the first few infusions. Inform your doctor if you have a history of allergies or any problems with previous cancer treatments.
• Infections: Since Daratumumab affects the immune system, it is important to monitor for signs of infection. You may be given additional medications to help prevent infections during treatment.
• Pregnancy and Breastfeeding: Daratumumab should not be used during pregnancy unless clearly needed, as its safety in pregnant women has not been established. It is also not recommended while breastfeeding, as it may pass into breast milk.
• Lung or Breathing Problems: If you have any lung diseases or respiratory issues, inform your healthcare provider, as Daratumumab can increase the risk of breathing difficulties or lung infections.

Daratumumab can interact with certain medications, so it is important to inform your healthcare provider about any other drugs you are taking. Some important interactions include:

• Vaccines: Daratumumab may reduce the effectiveness of certain vaccines, especially live vaccines, as it affects the immune system.
• Immunosuppressants: Since Daratumumab works by stimulating the immune system, using it alongside other immunosuppressive drugs may increase the risk of infections or affect how well the treatment works.
• Blood Thinners: Daratumumab may interact with anticoagulants or blood-thinning medications, which could increase the risk of bleeding.

Always inform your doctor about any other medications, including over-the-counter drugs and supplements, before starting Daratumumab.

The dosage of Daratumumab is determined by your doctor based on your specific condition. Generally, the treatment involves:

• Initial Infusions: Higher doses are given at the beginning of treatment, usually over several weeks.
• Maintenance Doses: After the initial cycle, maintenance doses are typically given every 2 to 4 weeks, depending on your response to treatment.

Your doctor will adjust the dosage if necessary to minimize side effects and maximize the effectiveness of the treatment.

Daratumumab is only available by prescription and is administered under the supervision of a healthcare provider in a clinical setting. It cannot be taken at home or self-administered. Your doctor will determine if Daratumumab is appropriate for your condition based on your medical history, the stage of your cancer, and your response to previous treatments.

1. What is Daratumumab used for?
   Treatment of multiple myeloma (a type of blood cancer).

2. How does Daratumumab work?
   It is a monoclonal antibody targeting CD38 on myeloma cells, helping the immune system destroy them.

3. Is Daratumumab a chemotherapy drug?
   No, it is an immunotherapy agent.

4. How is Daratumumab administered?
   Intravenous infusion or subcutaneous injection.

5. What cancers does Daratumumab treat?
   Primarily multiple myeloma, sometimes in combination with other drugs.

6. Can Daratumumab be used alone?
   Yes, but often given with other myeloma therapies.

7. What are common side effects of Daratumumab?
   Infusion reactions, fatigue, nausea, low blood counts, respiratory infections.

8. Are infusion reactions common with Daratumumab?
   Yes, especially during the first infusion.

9. How long is Daratumumab treatment?
   Treatment cycles vary; often continued until disease progression or toxicity.

10. Can Daratumumab affect blood test results?
    Yes, it can interfere with blood compatibility testing (blood typing).

11. Is Daratumumab safe during pregnancy?
    Its safety is not established; generally avoided during pregnancy.

12. What premedications are needed before Daratumumab?
    Steroids, antihistamines, and acetaminophen to reduce infusion reactions.

13. Can Daratumumab cause infections?
    Yes, it can increase risk of respiratory and other infections.

14. Is Daratumumab a targeted therapy?
    Yes, it specifically targets the CD38 protein on myeloma cells.

15. How often is Daratumumab given?
    Weekly initially, then less frequently as treatment progresses.

16. Can Daratumumab be combined with stem cell transplant?
    Yes, it is used before or after stem cell transplant in some protocols.

17. Is Daratumumab FDA-approved?
    Yes, approved for multiple myeloma treatment.

18. Does Daratumumab cause hair loss?
    Hair loss is not a common side effect.

19. What should patients avoid while on Daratumumab?
    Avoid live vaccines and report signs of infection promptly.

20. Is Daratumumab expensive?
    Yes, it is a high-cost medication typically covered by insurance or assistance programs.